1. Home
  2. IMMP vs MYPS Comparison

IMMP vs MYPS Comparison

Compare IMMP & MYPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.62

Market Cap

58.2M

Sector

Health Care

ML Signal

HOLD

Logo PLAYSTUDIOS Inc.

MYPS

PLAYSTUDIOS Inc.

HOLD

Current Price

$0.44

Market Cap

60.2M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMMP
MYPS
Founded
1987
2011
Country
Australia
United States
Employees
N/A
543
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
58.2M
60.2M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
IMMP
MYPS
Price
$0.62
$0.44
Analyst Decision
Hold
Buy
Analyst Count
3
2
Target Price
$5.50
$3.00
AVG Volume (30 Days)
22.9M
309.9K
Earning Date
04-23-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$445.09
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.29
$0.41
52 Week High
$3.53
$1.68

Technical Indicators

Market Signals
Indicator
IMMP
MYPS
Relative Strength Index (RSI) 40.17 43.58
Support Level $0.29 $0.42
Resistance Level $1.89 $0.53
Average True Range (ATR) 0.08 0.03
MACD 0.12 0.00
Stochastic Oscillator 42.48 26.15

Price Performance

Historical Comparison
IMMP
MYPS

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

About MYPS PLAYSTUDIOS Inc.

PLAYSTUDIOS Inc is engaged in gaming and related business. The Company develops and operates online and mobile social gaming applications (games or game), many of which incorporate a loyalty program offering real world rewards provided by a collection of awards partners. The Companies games are free-to-play and available via the Apple App Store, Google Play Store, Amazon Appstore and Facebook (collectively, platforms or platform operators). The Company creates games based on its own original content as well as third-party licensed brands. The Company generates revenue through the in-game sales of virtual currency and through advertising. The company has one operating segment with one business activity, developing and monetizing social games.

Share on Social Networks: